Provided herein are methods, devices and compositions for assessing neuromodulation efficacy based on changes in the level of one or more biomarkers in plasma or urine collected from a human subject following a renal neuromodulation procedure.

Embodiments herein include systems and methods for detecting, predicting and/or assessing acute kidney injury. In an embodiment, a monitoring system to detect acute kidney injury is included. The monitoring system can include a sensor circuit configured to collect renal data including at least one of systemic renal data, direct renal data, urinary tract data, and renal-relevant extracorporeal data. The monitoring system can also include a memory circuit to store collected renal data, an evaluation circuit to assess renal status, and a telemetry circuit. The evaluation circuit can determine whether acute kidney injury has occurred or is likely to occur by comparing the renal data to at least one of threshold values, personal historical values, patient population values and patterns indicative of acute kidney injury. The evaluation circuit can initiate a warning notification if acute kidney injury has occurred or is likely to occur. Other embodiments are also included herein.

A device for in vivo detecting and quantifying a concentration of an analyte in a peritoneal fluid of a subject. The device includes (a) a catheter having an open proximal end configured to be disposed external to the subject, an open distal end configured to be disposed within the peritoneal cavity comprising the peritoneal fluid, an anchor portion, an outer wall, and an inner wall, (b) a sensor disposed adjacent to the open distal end and configured to detect and quantify the concentration of the analyte in the peritoneal fluid, and (c) a main control unit disposed external to the subject, connected to the sensor via a wire, and configured to control the sensor, receive and store detection and quantification data from the sensor, and transmit the data to a second device. A portion of the wire is disposed between the inner wall and the outer wall of the catheter.

A microdevice for monitoring a target analyte is provided. The microdevice can include a field effect transistor comprising a substrate, a gate electrode, and a microfluidic channel including graphene. The microfluidic channel can be formed between drain electrodes and source electrodes on the substrate. The microdevice can also include at least one aptamer functionalized on a surface of the graphene. The at least one aptamer can be adapted for binding to the target analyte. Binding of the target analyte to the at least one aptamer can alter the conductance of the graphene.

Modules, systems and methods for clearing substances from a living body are disclosed. A module may include an instructions receiver configured to receive wireless transmissions of instructions from a master controller located outside of the body when the module is inside the body; an energy receiver configured to receive wireless transmission of non-destructive energy from the master controller located outside of the body when the module is inside the body; an energy converter configured to convert the non-destructive energy received to destructive energy; and an energy emitter configured to emit the destructive energy.

Apparatuses and methods for analyzing fluid samples are provided. For example, an example apparatus may include a fluid imaging chamber, at least one illumination source component, and an image sensor component. In some examples, the fluid imaging chamber comprises a flow channel for receiving a fluid sample. In some examples, the at least one illumination source component is configured to emit at least one light beam, and the at least one light beam is directed through the fluid sample in the flow channel from a top surface of the fluid imaging chamber. In some embodiments, the image sensor component is positioned under a bottom surface of the fluid imaging chamber and configured to generate digital holography image data of the fluid sample.

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Described here are meters and methods for sampling, transporting, and/or analyzing a fluid sample. The meters may include a meter housing and a cartridge. In some instances, the meter may include a tower which may engage one or more portions of a cartridge. The meter housing may include an imaging system, which may or may not be included in the tower. The cartridge may include one or more sampling arrangements, which may be configured to collect a fluid sample from a sampling site. A sampling arrangement may include a skin-penetration member, a hub, and a quantification member.

A method (1500) for deriving a mental state of a subject is disclosed. The method comprises receiving (1502) a bio-signal from the subject; calculating respective statistical variations of at least two physiological parameters derived from the bio-signal; determining (1504) an arousal level of the subject based on the calculated statistical variations of the at least two physiological parameters; deriving a time-domain heart rate variability signal from the bio-signal for calculating at least two heart rate variability parameters; determining (1506) a valence level of the subject based on the at least two heart rate variability parameters; and deriving (1508) the mental state from the arousal level and valence level. A related apparatus is also disclosed.

An injector for transcutaneously introducing a sensor into a patient, including a cannula, a base element, a sliding element arranged displaceably on the base element, for transcutaneously introducing the cannula into the patient in an injection direction, and including an ejection element for automatically pulling the cannula out of the patient counter to the injection direction by the ejection element in an ejection operation. The injector has a locking element for the ejection element such that, in a delivery state, the ejection element is lockable in an energy-charged state, and the sliding element and the locking element are configured to interact indirectly or directly in order, in an injection state, when the cannula is introduced transcutaneously into the patient, to release the locking of the ejection element in order automatically to start the ejection operation.